These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25944732)

  • 1. High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment.
    Tsubakihara Y; Akizawa T; Iwasaki M; Shimazaki R
    Ther Apher Dial; 2015 Oct; 19(5):457-65. PubMed ID: 25944732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients.
    Tsubakihara Y; Gejyo F; Nishi S; Iino Y; Watanabe Y; Suzuki M; Saito A; Akiba T; Hirakata H; Akizawa T
    Ther Apher Dial; 2012 Dec; 16(6):529-40. PubMed ID: 23190512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
    Hayashi T; Uemura Y; Kumagai M; Kimpara M; Kanno H; Ohashi Y;
    Clin Exp Nephrol; 2019 Mar; 23(3):349-361. PubMed ID: 30291472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study.
    Akizawa T; Tsubakihara Y; Hirakata H; Watanabe Y; Hase H; Nishi S; Babazono T; Kumagai M; Katakura S; Uemura Y; Ohashi Y;
    Clin Exp Nephrol; 2016 Dec; 20(6):885-895. PubMed ID: 26779906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease .
    Akaishi M; Hiroe M; Hada Y; Suzuki M; Tsubakihara Y; Akizawa T;
    J Cardiol; 2013 Oct; 62(4):249-56. PubMed ID: 23787155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
    Galle JC; Addison J; Suranyi MG; Claes K; Di Giulio S; Guerin A; Herlitz H; Kiss I; Farouk M; Manamley N; Wirnsberger G; Winearls C
    Nephrol Dial Transplant; 2016 Dec; 31(12):2073-2085. PubMed ID: 27190334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
    Inrig JK; Barnhart HX; Reddan D; Patel UD; Sapp S; Califf RM; Singh AK; Szczech LA
    Am J Kidney Dis; 2012 Sep; 60(3):390-401. PubMed ID: 22537421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
    Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL
    Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study.
    Kim Y; Park SK; Cho WY; Joo KW; Shin SK; Kim DJ; Kim YL; Son SH; Chung W; Lee KY; Park SK; Kim JK; Kim SW; Kang DH; Kim JK; Jeon JS; Lee KW; Lee CH; Oh DJ; An WS; Lee JS; Kang GW; Do JY; Lee JP; Jin K
    BioDrugs; 2020 Feb; 34(1):99-110. PubMed ID: 31749113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.
    Suzuki M; Hada Y; Akaishi M; Hiroe M; Aonuma K; Tsubakihara Y; Akizawa T
    Int Heart J; 2012; 53(4):238-43. PubMed ID: 22878802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How the Target Hemoglobin of Renal Anemia Should Be.
    Mimura I; Tanaka T; Nangaku M
    Nephron; 2015; 131(3):202-9. PubMed ID: 26381503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
    Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
    Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
    Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.